We reviewed consecutive, prevalence, clinical CT lung screening examinations performed at our institution from January 2012 through May 2014. To qualify for screening, individuals had to satisfy the NCCN high-risk criteria for lung cancer, be asymptomatic, have

physician orders for CT lung screening, be free of lung cancer for ≥5 years, and have no known metastatic disease 3 and 5. All CT lung screening examinations were performed on ≥64-row multidetector CT scanners (LightSpeed VCT and Discovery VCT [GE Medical Systems, Milwaukee, PD0325901 mouse Wisconsin]; Somatom Definition [Siemens AG, Erlangen, Germany]; iCT [Philips Medical Systems, Andover, Massachusetts]) at 100 kV and 30 to 100 mA depending on the scanner and the availability of iterative reconstruction software. Axial images

were obtained at 1.25- to 1.5-cm thickness with 50% overlap and reconstructed with both soft tissue and lung kernels. Axial maximum-intensity projections (16 × 2.5 mm) and coronal and sagittal multiplanar reformatted images were reconstructed and used for interpretation. Original image interpretation was performed by radiologists specifically trained and credentialed in CT lung screening using a structured www.selleckchem.com/products/BKM-120.html reporting system and the NCCN guidelines nodule follow-up algorithms 3 and 5. Positive results required the identification of a solid, noncalcified nodule ≥4 mm or a nonsolid nodule ≥5 mm for which >2-year stability had not been established [5]. Studies positive for solid nodules <6 mm, nonsolid nodules <2 cm, and positive nodules stable for >3 months but <2 years were recategorized Bumetanide as benign to estimate the hypothetical ACR Lung-RADS positive rate and PPV in our cohort. Cases reclassified as benign would be considered false negative if cancer was diagnosed within 12 months of the baseline examination. For both ACR Lung-RADS and the original interpretation, solid and part-solid nodules >8 mm, growing nodules, and nonsolid nodules with growing solid components were categorized as “suspicious.” All other positive nodules were categorized as “probably benign.” Mediastinal and hilar lymph nodes measuring >1 cm in the

short axis in the absence of pulmonary nodules and findings suspicious for infection or inflammation (most commonly areas of tree-in-bud nodularity) not currently considered positive under ACR Lung-RADS were treated as incidental findings under both schemas. From January 2012 through May 2014, a total of 2,180 high-risk patients underwent clinical prevalence CT lung screening examinations (Table 1). Five hundred seventy-seven of these 2,180 (26%) were patients from outside our institution for whom clinical follow-up after the prevalence CT lung screening examination was not available during this retrospective review. Application of ACR Lung-RADS had the following impact in our specific patient cohort. Three hundred seventy of 2,180 examinations (17.